PLA2G7 and cardiovascular disorder: The studies performed in last few years have led to the introduction of LpPLA2 in The Cardiovascular Disease Risk Assessment Guidelines in 2008 [4], and in The European Guidelines on cardiovascular disease prevention in clinical practice in 2012 [5].